Interactions in the mucosal microenvironment: Vasoactive intestinal peptide modulates the down-regulatory action of Lactobacillus rhamnosus on LPS-induced interleukin-8 production by intestinal epithelial cells

Microbial Ecology in Health and Disease

Volumn 19, Issue 3, 2007, Pages 191-200

  Wood, Christine ^a   Keeling, Suzanne ^b   Bradley, Shannon ^b   Johnson Green, Perry ^a,b   Green Johnson, Julia M ^b  

^a ACADIA UNIVERSITY   (Canada)

^b UNIVERSITY OF ONTARIO INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

Interleukin 8; Intestinal epithelial cell; Lactobacilli; Probiotics; Vasoactive intestinal peptide

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; INTERLEUKIN 8; LACTIC ACID; LIPOPOLYSACCHARIDE; NEUROPEPTIDE; PROTEIN KINASE C; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVATION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INTESTINE EPITHELIUM CELL; LACTOBACILLUS RHAMNOSUS; MICROENVIRONMENT; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL;

LACTOBACILLUS RHAMNOSUS; NEGIBACTERIA;

EID: 34548607964     PISSN: 0891060X     EISSN: 16512235     Source Type: Journal    
DOI: 10.1080/08910600701278722     Document Type: Article

References (45)

1. Christ AD, Blumberg RS. The intestinal epithelial cell: immunological aspects. Springer Semin Immunopathol. 1997;18:449-61.
2. Nagler-Anderson C. Man the barrier! Strategic defences in the intestinal mucosa. Nat Rev Immunol. 2001;1:59-77.
3. Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol. 2000;278:C4561-2.
4. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-8.
5. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, et al. Prokaryotic regulation of epithelial responses by inhibition of IkB-α ubiquitination. Science. 2000;289:1560-3.
6. Naidu AS, Bidlack WR, Clemens RA. Probiotic spectra of lactic acid bacteria. Crit Rev Food Sci Nutr. 1999;39:13-136.
7. Cross ML. Immunoregulation by probiotic lactobacilli: pro-Th1 signals and their relevance to human health. Clin Appl Immunol Rev. 2002;3:115-25.
8. Green-Johnson JM. Probiotics and the immune system: basic aspects. Proceedings of the Montreal International Probiotic Symposium, 2005.
9. Wallace T, Bradley S, Buckley N, Green-Johnson J. Interactions of lactic acid bacteria with human intestinal epithelial cells: effects on cytokine production. J Food Protect. 2003;66:466-72.
10. Schuerer-Maly CC, Eckmann L, Kagnoff MF, Falco MT, Maly FE. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994;81:85-91.
11. Hersh D, Weiss J, Zychlinsky A. How bacteria initiate inflammation: aspects of the emerging story. Curr Opin Microbiol. 1998;1:43-8.
12. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001;50:491-5.
13. Olsson C, Holmgren S. The control of gut motility. Comp Biochem Physiol. 2001;128:481-503.
14. Alleaume C, Eychene A, Caigneaux E, Muller J-M, Philippe M. Vasoactive intestinal peptide stimulates proliferation in HT29 human colonic adenocarcinoma cells: concomitant activation of Ras/Rap1-B-Raf-ERK signaling pathway. Neuropeptides. 2003;37:98-104.
15. Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med. 2003;9:211-7.
16. Delgado M. VIP: a very important peptide in T helper differentiation. Trends Immunol. 2003;24:221-4.
17. Voice JK, Dorsamm G, Chan RC, Grinninger C, Kong Y, Goetzl EJ. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept. 2002;109:299-308.
18. Takahashi K, Fukushima K, Sasaki I, Ogawa H, Sato S, Naito H, et al. Identification of cells responding to VIP by measuring intracellular cAMP in human colonic mucosa. Scand J Gastroenterol. 2000;35:737-41.
19. Fogh J, Trempe G. A colonic adenocarcinoma cell line of human origin. In: Fogh J, editor. Human tumor cells in vitro. New York: Plenum Press; 1975. p. 115-59.
20. Sekiguchi M, Sakakibara I, Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med. 1978;48:61-8.
21. Fishbein VA, Coy DH, Hocart SJ, Jiang NY, Mrozinski JE Jr, Maney SA, et al. A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Peptides. 1994;15:95-100.
22. Marchis-Mouren G, Martin J-M, Luis J, El Battari A, Muller J-M, Marvaldi J, et al. HT-29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP): VIP receptor structure and metabolism. Biochimie. 1988;70:663-71.
23. De La Fuente M, Delgado M, del Rio M, Martinez C, Herranz A, Gomariz RP. Stimulation by VIP of phagocytic function in rat macrophages. Protein kinase C involvement. Regul Pept. 1993;48:345-53.
24. Haller D, Bodes C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79-87.
25. Vidal K, Donnet-Hughes A, Granato D. Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect Immun. 2002;70:2057-64.
26. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol. 2002;97:1182-6.
27. Gill HS, Rutherford KJ. Viability and dose-response studies on the effects of the immunoenhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br J Nutr. 2001;86:285-9.
28. Ha CL, Lee JH, Zhou HR, Ustunol Z, Pestka JJ. Effects of yogurt ingestion on mucosal and systemic cytokine gene expression in the mouse. J Food Protect. 1999;62:181-8.
29. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, et al. Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A. 2005;102:10321-6.
30. Schuerer-Maly C-C, Eckmann L, Kagnoff MF, Falco MT, Maly F-E. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994;81:85-91.
31. Delgado M, Ganea D. Is vasoactive intestinal peptide a type 2 cytokine? J Immunol. 2001;166:2907-12.
32. Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor κB-dependent transcriptional activity. Biochem Biophys Res Commun. 2003;312:275-83.
33. Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun. 2003;301:825-32.
34. Mullol J, Baraniuk JN, Pitale M, Benfield T, Logun C, Picado C, et al. Vasoactive intestinal peptide (VIP) induces IL-6 and IL-8, but not G-CSF and GM-CSF release from a human bronchial epithelial cell line. Neuropeptides. 1997;31:119-24.
35. Pascual DW, Kiyono H, McGhee JR. The enteric nervous and immune systems: interactions for mucosal immunity and inflammation. Immunomethods. 1994;5:56-72.
36. Renzi D, Mantellini P, Calabro A, Panerai C, Amorosi A, Paladini I, et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Ital J Gastroenterol Hepatol. 1998;30:62-70.
37. Kubota Y, Petras RE, Ottaway CA, Tubbs RR, Farmer RG, Fiocchi C. Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology. 1992;102:1242-51.
38. Wang H-Y, Jiang X, Gozes I, Fridkin M, Brenneman DE, Ganea D. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regul Pept. 1999;84:55-67.
39. Matsuguchi R, Takagi A, Matsuzaki T, Nagaoka M, Ishikawa K, Yokokura T, et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumour necrosis factorα-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol. 2003;10:259-66.
40. Miettinen M, Lehtonen A, Julkunen I, Matikainen S. Lactobacilli and streptococci activate NF-κB and STAT signaling pathways in human macrophages. J Immunol. 2000;164:3733-40.
41. Vinderola G, Matar C, Perdigon G. Role of intestinal epithelial cells in immune effects mediated by Gram-positive probiotic bacteria: involvement of Toll-like receptors. Clin Diagn Lab Immunol. 2005;12:1075-84.
42. Bai A-P, Ouyang Q, Zhang W, Wang C-H, Li S-F. Probiotics inhibit TNFα-induced IL-8 secretion of HT-29 cells. World J Gastroenterol. 2004;10:455-7.
43. Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. 2006;176:1228-37.
44. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumour necrosis factor alpha-induced interleukin-8 expression. Infect Immun. 2004;72:5308-14.
45. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol. 2000;165:2955-61.